Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.
ATTO, BLDP, NTB, CCJ and EBS have been added to the Zacks Rank #5 (Strong Sell) List on August 2, 2021.
Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.